Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cephalon drug provokes robust response in NHL patients

Cephalon drug provokes robust response in NHL patients

9th November 2009

Cephalon has revealed that its drug Treanda (bendamustine HCI) provoked a durable response in patients suffering from relapsed indolent non-Hodgkin’s Lymphoma (NHL) during a recent clinical trial.

This result applies to those patients whose disease had progressed during or within six months of treatment with alternative therapy Rituximab.

The results of the study show that 75 per cent of patients who were administered the drug intravenously displayed a response, with 14 per cent showing a complete response to the drug.

NHL is a slow-growing, but serious cancer that affects the lymphatic system of sufferers.

Brad Kahl, associate professor at the University of Wisconsin’s Paul Cerbone Comprehensive Cancer Centre, stated: “Bendamustine provides physicians and patients with another valuable treatment option for recurring indolent B-cell NHL, a patient population that continues to grow.”

Meanwhile, last month Cephalon announced a new appointment ? that of Bob Repella – who the firm employed as its senior vice-president of pharmaceutical operations.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.